

Solid Biosciences Inc. Logo

## **Solid Biosciences to Present at the Credit Suisse Healthcare Conference**

November 9, 2018

CAMBRIDGE, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will present at the Credit Suisse 27<sup>th</sup> Annual Healthcare Conference on Wednesday, November 14, 2018 at 2:50 pm MT in Scottsdale, Arizona.

The Credit Suisse Healthcare Conference will be webcast live under the investor relations section of Solid Biosciences' website at [www.solidbio.com](http://www.solidbio.com) and will be archived there following the presentation for 30 days.

### **About Solid Biosciences**

Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. For more information, please visit [www.solidbio.com](http://www.solidbio.com).

### **Media Contact:**

Solid Biosciences

Kate Niazi-Sai

617-337-4680

[media@solidbio.com](mailto:media@solidbio.com)

### **Investor Contact:**

Kendall Investor Relations

Carlo Tanzi, Ph.D.

617-337-4680

[investors@solidbio.com](mailto:investors@solidbio.com)



Source: Solid Biosciences Inc.